SMNR — Semnur Pharmaceuticals Share News
0.000.00%
- $139.36m
- $142.35m
Brief: Scilex Announces S-4 Effectiveness for Denali–Semnur Merger Proposal
Brief: Denali Capital Shareholders Approve Extension For Business Combination Deadline
Brief: Denali Capital Acquisition Announces Extension Of Deadline To Complete Business Combination
Brief: Denali Capital Acquisition Corp. Announces Extension Of Deadline To Complete Business Combination
Brief: Denali Capital Acquisition Corp Says Not In Compliance With Nasdaq Listing Rule 5450(B)(2)(A)
Brief: Denali Capital Acquisition Corp. Announces Extension Of Deadline To Complete Business Combination
Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal (updated)
Brief: Denali Capital Acquisition Corp Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital (updated)
Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital
Brief: Denali Capital Acquisition Corp. Announces Extension Of Deadline To Complete Business Combination
Brief: Denali Capital Acquisition Announces Extension Of Deadline To Complete Business Combination
Brief: Denali Capital Acquisition Corp Announces Extension Of Deadline To Complete Business Combination
Brief: Denali Capital Acquisition Announces Extension Of Deadline To Complete Business Combination
Brief: Denali Capital Acquisition Corp. Announces Extension Of Deadline To Complete Business Combination
Brief: Denali Capital Acquisition Announces Extension of Deadline to Complete Business Combination
Brief: Denali Capital Acquisition Announces Extension Of Deadline To Complete Business Combination
Brief: Denali Capital Acquisition Corp. Announces Extension Of Deadline To Complete Business Combination
Brief: Denali Capital Acquisition Corp. Announces Shareholder Approval Of Extension Of Deadline To Complete Business Combination